Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

31 citing papers in PubMed.

1. Clinical course and biomarkers in patients with type 1 Gaucher disease and Parkinson's disease: A retrospective cohort study.Molecular genetics and metabolism reports · 2026
   Article
2. Case Report: Progressive myoclonus epilepsy as an early manifestation of neuronopathic Gaucher disease.Frontiers in neuroscience · 2026
   Article
3. Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson's disease and dementia with Lewy bodies.Nature communications · 2025
   Article
4. Cholinergic Degeneration and Cognitive Function in Early GBA1-Related Parkinson's Disease.Annals of neurology · 2025
   Article
5. Variant-specific effects of GBA1 mutations on dopaminergic neuron proteostasis.Journal of neurochemistry · 2024
   Article
6. Uncovering a New Family Cluster of Gaucher Disease: A Case Report.Cureus · 2024
   Article
7. Gaucher disease - more than just a rare lipid storage disease.Journal of molecular medicine (Berlin, Germany) · 2022
   Review
8. Cognitive Functioning of Glucocerebrosidase (Frontiers in neurology · 2021
   Article
9. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.Scientific reports · 2020
   Article
10. Gaucher Disease: New Expanded Classification Emphasizing Neurological Features.Iranian journal of child neurology · 2019
    Review
11. Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson's Disease.Frontiers in neuroscience · 2019
    Review
12. The Spectrum of Neurological Manifestations Associated with Gaucher Disease.Diseases (Basel, Switzerland) · 2017
    Review
13. Glucocerebrosidase and parkinsonism: lessons to learn.Journal of neurology · 2016
    Article
14. Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.PLoS genetics · 2016
    Article
15. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.FEBS letters · 2015
    Review
16. Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson's disease.Journal of human genetics · 2015
    Article
17. Genetic convergence of Parkinson's disease and lysosomal storage disorders.Molecular neurobiology · 2015
    Review
18. Effect of GBA Mutations on Phenotype of Parkinson's Disease: A Study on Chinese Population and a Meta-Analysis.Parkinson's disease · 2015
    Article
19. The significance of GBA for Parkinson's disease.Journal of inherited metabolic disease · 2014
    Review
20. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.JAMA neurology · 2014
    Article

Corrections and comments

• Comment on
  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.2009

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as